Medtown Ventures Scouts for Life Science Deals with $500MM Investor Pool
March 20, 2014
Medtown Ventures Launches Round2funding, an Invitation Only Investor Portal
March 25, 2014
CellectCell, Inc. Announces Georgia Research Alliance Phase II Funding for the Commercialization of Novel Cell Isolation Technology
October 6, 2015
MARIETTA, Ga. (October 6, 2015) -- CellectCell, Inc., a company that develops novel cell selection and isolation technology, announced today the receipt of Phase II funding from the Georgia Research Alliance (GRA).
CellectCell’s initial focus is the commercializat
ion of a disposable cell culture cartridge for academic and commercial research. This product is developed from adhesion strength-based isolation techniques discovered by researchers at the Georgia Institute of Technology and exclusively licensed by CellectCell from the Georgia Tech Research Corporation. CellectCell will use the GRA Phase II funding to advance the technology through design & development into scale-up, manufacturing and commercial launch.
“We are excited to be collaborating with GRA to take this breakthrough cell selection and isolation technology and transform it into products that will allow research laboratories and manufacturing companies to select for specific cell types with higher sensitivity and specificity than currently available isolation techniques,” stated Rebecca Marshall, President of CellectCell. “Because the technology is based on the natural properties of cells and is label-free, the process does not adversely affect cell viability or phenotype. We believe CellectCell has the potential to revolutionize the way stem cells and their progeny are isolated for research, diagnostic and therapeutic applications.”
The GRA Ventures Program has launched 150 new companies and created nearly 1,400 jobs. GRA’s portfolio of companies has attracted more than $778 million in equity investment to date.
“We are pleased to continue building a reputation for Georgia as a center of discovery and invention by investing in the commercialization of this new technology,” said H. Lee Herron, VP, Commercialization, Georgia Research Alliance. “We believe adhesion strength-based cellular selection is groundbreaking technology, and are encouraged to see it find a home in CellectCell, Inc. with an experienced team of entrepreneurs and scientists behind it. This is an exciting step forward for Georgia Tech and the bioscience industry.”
About CellectCell, Inc.:
CellectCell, Inc. is an early-stage company dedicated to developing and commercializing label-free cell selection and isolation technology based on the natural adherent properties of cells and the principles of microfluidics. CellectCell is developing a disposable cell culture cartridge that can be used to positively or negatively select for specific cell types rapidly and with high specificity, sensitivity and purification efficiency. CellectCell, Inc. was formed in 2015 by Medtown Ventures LLC together with the inventors of the cell selection technology. Visit www.CellectCell.com for more information.
About the Georgia Research Alliance:
The Georgia Research Alliance (GRA) works to expand research and commercialization capacity in Georgia’s universities to recruit world-class talent, seed new companies and transform lives. For twenty-five years, GRA has worked to strengthen the research enterprise in Georgia by working in partnership with the University System of Georgia and the Georgia Department of Economic Development to create the companies and jobs of Georgia’s future. Visit www.gra.org for more information.
Any questions or comments can be directed to Rebecca Marshall, President, CellectCell, Inc. at email@example.com.